Akari Therapeutics Plc announced that the U.S. Food and Drug Administration granted Fast Track designation for nomacopan for the treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA) in pediatric patients.
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00GlobeNewswirehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngGlobeNewswire2019-08-14 08:00:382019-08-14 13:02:01Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for Pediatric HSCT-TMA
